Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab
Rheumatology key message . Rates of live births were reassuring in women with RA exposed to rituximab before conception.
SIR, In women with RA, information concerning the exposure risk to rituximab (RTX) during pregnancy is limited. RTX, an mAb, can cross the placenta from the second trimester, has a long half-life, estimated to be between 18 and 23 days, and lymphocyte depletion is variable and possibly longstanding. Hence, the current Summary of Product Characteristics states that women should take contraception during RTX treatment and for 12 months after finishing RTX treatment [1] . In this analysis, we summarize the pregnancy outcomes of women with RA receiving RTX before or during pregnancy in the British Society for Rheumatology Biologics Register in RA (BSRBR-RA). This register systematically captures information on RA patients exposed to biologic therapy to monitor long-term safety [2] . The North-West MultiCentre Research Ethics Committee granted Ethical approval for the BSRBR-RA. Patients gave informed written consent. This study did not require additional approval or consent. Following the report of a pregnancy, additional data are collected via a pregnancy event proforma, including information on exposure to medications, on pregnancy outcome and on complications/congenital malformations. We included all patients with a reported pregnancy up to 18 December 2015 exposed to RTX at any point before pregnancy end and divided exposure into the following three groups: exposed within 6 months before conception, between 6 and 12 months before conception, and longer than 12 months before conception.
A total of 32 pregnancies (including 1 twin pregnancy) in 23 women were reported ( Table 1 ). The mean (range) age at conception was 34 (2041) years. No women received RTX during pregnancy. Of 27 known pregnancy outcomes, 21 (66%) were live births, 2 (6%) stillborn, 3 (9%) miscarriages and 2 (6%) terminations. The median (range) gestational length of live births (available for 18 pregnancies) was 38 (2942) weeks. Preterm delivery, defined as gestation <37 weeks, occurred in 4/18 (22%). Unfortunately, no data on immunoglobulin levels or lymphocyte counts in either mothers or newborns were recorded in the BSRBR-RA.
Ten women reported RTX exposure 6 months before conception [median (range) time of exposure was 3 (15) months], with the outcome known in 9, as follows: 6 live births, 1 stillbirth after 27 weeks (placental insufficiency), 1 miscarriage and 1 termination after 5 weeks. Four (40%) women were receiving MTX at conception. The woman who miscarried received MTX until Letters to the Editor ! The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com confirmation of pregnancy. Three infections were reported, as follows: one throat infection, one chest infection and three urinary tract infections (in one patient), for which hospitalization was required on one occasion, but these patients delivered three healthy newborns. RTX was restarted by 8/10 women, after a median (range) of 4 (213) months post-delivery.
Eight women reported RTX exposure between 6 and 12 months before conception. The median (range) time since last RTX exposure was 9 (611) months. Three women were receiving MTX at conception. The outcome was known in seven pregnancies, as follows: six live births and one miscarriage (patient receiving MTX). One live birth was a twin pregnancy, for which one baby was born alive and the other died in utero. In another case, one newborn was reported to have a heart murmur, although a specific diagnosis was not recorded. In one case, maternal pericardial effusion and pleuritic chest pain during pregnancy were reported. Another woman suffered from a postpartum haemorrhage. RTX was restarted by 5/8 women, after a median (range) time of 1 (12) months post-delivery.
Fourteen women reported RTX exposure longer than 12 months before conception [median (range) time between conception and exposure was 20 (1289) months]. Three women received MTX at conception. For two pregnancies, tocilizumab (stopped 4 months before conception) and etanercept (stopped 1 month before conception) were started between RTX discontinuation and conception. Of 12 pregnancies with known outcomes, there were 9 live births, 1 stillbirth at 26 weeks (attributable to placental insufficiency, which was recurrent in the same patient as presented earlier), 1 termination at 8 weeks and 1 miscarriage at 5 weeks (patient receiving MTX). The patient receiving tocilizumab had a termination, whereas the patient receiving etanercept had a live birth. RTX was restarted by 7/14 women, after a median (range) time of 4 (27) months postdelivery. Both women on alternative biologic therapy restarted the same biological.
In general, the rates of live births (66%) and the absence of major congenital malformations or evidence of maternal harm were reassuring. The largest retrospective study on pregnancy outcomes across different diseases reported a similar number of live births (59%) [3] . Recent BSR guidelines recommend that RTX be stopped at least 6 months before conception [4] . In the present study, 69% of women stopped RTX at least 6 months before conception, with no doses given after conception. The present report constitutes the largest prospectively collected case series of pregnancies following RTX for RA, with standardized data gathering. These reports are needed because evidence on pregnancy after exposure to RTX is scarce. However, 32 pregnancies remain a relatively small number, making it difficult to draw definite conclusions about any effect of RTX exposure on pregnancy. Given that some women have pregnancies taking place in different RTX exposure periods before conception, the sum of pregnant women in the three exposure groups differs from the total number of pregnant women. b RTX infusions given within 14 days of each other are counted as one course of RTX. c Twin pregnancy resulting in a single live birth and a still birth. RTX: rituximab.
